Effect of Different Neoadjuvant Chemotherapy Regimens on Pathological Complete Response Rate of Patients with Triple-Negative Breast Cancer
Objective To compare the effects of different neoadjuvant chemotherapy regimens on pathological complete response rate in patients with triple-negative breast cancer.Methods The clinical data of one hundred and twenty patients diagnosed with triple-negative breast cancer and receiving neoadjuvant chemotherapy in Suzhou Ninth People's Hospital from January 2015 to April 2021 were retrospectively analyzed,and they were divided into group A、group B and group C according to different chemotherapy protocols,with 40 cases in each group.Group A accepted NabPCb regimen,group B accepted TCb regimen,and group C accepted EC-T regimen.The clinical efficacy,tumor marker levels,median progression-free survival time and survival rate of the three groups were compared.Results The total effective rate of group A was 77.50%,which was higher than 67.50%and 70.00%of group B and group C,and the difference between the groups was statistically significant(P<0.05).The pathological complete response rate of group A was 36.67%,which was higher than 30.00%and 28.33%of group B and group C,and the difference between the groups was statistically significant(P<0.05).After treatment,the levels of carbohydrate antigen 15-3,carcinoembryonic antigen and human epidermal growth factor receptor-2 in the three groups were lower than before treatment,and the levels of all indexes in group A were lower than those in group B and group C,and the differences between the groups were statistically significant(P<0.05).The median progression-free survival time of group A was longer than that of group B and group C,and the difference between the groups was statistically significant(P<0.05).The 3-year survival rate of group A was higher than that of group B and group C,and the difference between the groups was statistically significant(P<0.05).Conclusion Different neoadjuvant chemotherapy regiments have significant effects on pathological complete response rate and survival indicators of patients with triple-negative breast cancer,among which NabPCb regimen shows significant advantages in improving pathological complete response rate,reducing tumor marker levels and proending progression-free survival time,and is recommended for clinical priority.
Triple-Negative breast cancerNeoadjuvant chemotherapyEfficacyPathological complete response rateTumor markersSurvival rate
万方数据
